Pitfalls in the diagnosis of prostatic cancer: Retrospective review of 1791 cases with clinical outcome

Histopathology

Volumn 51, Issue 4, 2007, Pages 452-457

  Berney, D M ^a   Fisher, G ^b   Kattan, M W ^c   Oliver, R T D ^a   Moller H ^d   Fearn, P ^e   Eastham, J ^e   Scardino, P ^e   Cuzick, J ^b   Reuter, V E ^e   Foster, C S ^f  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c LERNER RESEARCH INSTITUTE   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Atypical adenomatous hyperplasia; Biopsy; Error; Prostate

Indexed keywords

ARTICLE; ATROPHY; CANCER DIAGNOSIS; CANCER MORTALITY; COHORT ANALYSIS; DIAGNOSTIC ERROR; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOLOGIST; PRIORITY JOURNAL; PROSTATE ADENOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; UNITED KINGDOM;

DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; EDUCATION, MEDICAL, CONTINUING; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; PATHOLOGY; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 34548751762     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02819.x     Document Type: Article

References (25)

1. Brawer MK, Benson MC, Bostwick DG et al. Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer. Semin. Urol. Oncol. 1999 17 206 221.
2. Gumus BH, Nese N, Gunduz MI, Kandiloglu AR, Ceylan Y, Buyuksu C. Does asymptomatic inflammation increase PSA? A histopathological study comparing benign and malignant tissue biopsy specimens. Int. Urol. Nephrol. 2004 36 549 553.
3. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van ME. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur. Urol. 2000 37 404 412.
4. Philip J, Ragavan N, Desouza J, Foster CS, Javle P. Effect of peripheral biopsies in maximising early prostate cancer detection in 8-, 10- or 12-core biopsy regimens. BJU. Int. 2004 93 1218 1220.
5. Durkan GC, Sheikh N, Johnson P, Hildreth AJ, Greene DR. Improving prostate cancer detection with an extended-core transrectal ultrasonography- guided prostate biopsy protocol. BJU. Int. 2002 89 33 39.
6. Liu IJ, Macy M, Lai YH, Terris MK. Critical evaluation of the current indications for transition zone biopsies. Urology 2001 57 1117 1120.
7. Biedrzycki O, Varma M, Berney DM. Variations in the processing of prostatic needle cores in the UK; what is safe? J. Clin. Pathol. 2003 56 341 343.
8. Varma M, Berney DM, Jasani B, Rhodes A. Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. J. Clin. Pathol. 2004 57 687 690.
9. Cuzick J, Fisher G, Kattan MW et al. Long-term outcome among men with conservatively treated localised prostate cancer. Br. J. Cancer 2006 95 1186 1194.
10. Gaudin PB, Reuter VE. Benign mimics of prostatic adenocarcinoma on needle biopsy. Anat. Pathol. 1997 2 111 134.
11. Foster CS, Sakr WA. Proliferative lesions of the prostate that mimic carcinoma. Curr. Diagn. Path. 2001 7 194 212.
12. Jones EC, Young RH. The differential diagnosis of prostatic carcinoma. Its distinction from premalignant and pseudocarcinomatous lesions of the prostate gland. Am. J. Clin. Pathol. 1994 101 48 64.
13. Wojno KJ, tiftein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am. J. Surg. Pathol. 1995 19 251 260.
14. Molinie V, Herve JM, Lebret T et al. Value of the antibody cocktail anti p63 + anti p504s for the diagnosis of prostatic cancer. Ann. Pathol. 2004 24 6 16.
15. Davis LD, Zhang W, Merseburger A et al. p63 Expression profile in normal and malignant prostate epithelial cells. Anticancer Res. 2002 22 3819 3825.
16. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am. J. Clin. Pathol. 2005 123 231 236.
17. Luque RJ, Lopez-Beltran A, Perez-Seoane C, Suzigan S. Sclerosing adenosis of the prostate. Histologic features in needle biopsy specimens. Arch. Pathol. Lab. Med. 2003 127 e14 e16.
18. Bostwick DG, Chang L. Overdiagnosis of prostatic adenocarcinoma. Semin. Urol. Oncol. 1999 17 199 205.
19. Epstein JI, Walsh PC, Sanfilippo F. Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy. Am. J. Surg. Pathol. 1996 20 851 857.
20. Dodson AR, Foster CS. The role of immunohistochemistry in the problematic prostate biopsy. Recent Advances in Histopathology. J Underwood M Pignatelli, eds. London : The Royal Society of Medicine Press, 2005 105 136.
21. Rubin MA, Zhou M, Dhanasekaran SM et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002 287 1662 1670.
22. Skinnider BF, Oliva E, Young RH, Amin MB. Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am. J. Surg. Pathol. 2004 28 701 705.
23. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod. Pathol. 2002 15 1302 1308.
24. Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br. J. Cancer 2006 94 1361 1368.
25. http://www.uropathology.org. Accessed on 28 August 2007.